CDKN2A and melanoma: Together, these data suggest that genomic profiling of phenotypically normal SF can help identify novel molecular targets for chemoprevention, including early specific biomarkers of melanoma risk among individuals who are heterozygous for CDKN2A mutations within FM families; these potential biomarkers would enable mechanism-based early detection of melanoma and personalized prevention strategies to target sporadic melanoma.